CA2993996A1 - Use of anti-cd40 antibodies for treatment of lupus nephritis - Google Patents

Use of anti-cd40 antibodies for treatment of lupus nephritis Download PDF

Info

Publication number
CA2993996A1
CA2993996A1 CA2993996A CA2993996A CA2993996A1 CA 2993996 A1 CA2993996 A1 CA 2993996A1 CA 2993996 A CA2993996 A CA 2993996A CA 2993996 A CA2993996 A CA 2993996A CA 2993996 A1 CA2993996 A1 CA 2993996A1
Authority
CA
Canada
Prior art keywords
seq
antibody
sequence
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2993996A
Other languages
English (en)
French (fr)
Inventor
Scott Ronald Brodeur
Thomas B. Freeman
Gerald Henry NABOZNY
Meera RAMANUJAM
Paul SCHOLL
Juergen STEFFGEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA2993996A1 publication Critical patent/CA2993996A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2993996A 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis Pending CA2993996A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US62/212,810 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US62/257,336 2015-11-19
US201662287587P 2016-01-27 2016-01-27
US62/287,587 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
CA2993996A1 true CA2993996A1 (en) 2017-03-09

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2993996A Pending CA2993996A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Country Status (16)

Country Link
US (3) US20170058038A1 (https=)
EP (1) EP3344655B1 (https=)
JP (2) JP2018529661A (https=)
KR (1) KR20180039172A (https=)
CN (1) CN107922501A (https=)
AU (1) AU2016317028B2 (https=)
BR (1) BR112018001907A2 (https=)
CA (1) CA2993996A1 (https=)
CL (1) CL2018000317A1 (https=)
DK (1) DK3344655T5 (https=)
ES (1) ES2969968T3 (https=)
HU (1) HUE063528T2 (https=)
MX (1) MX390653B (https=)
PH (1) PH12018500445B1 (https=)
PL (1) PL3344655T3 (https=)
WO (1) WO2017040566A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US20200299400A1 (en) * 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
US20240254248A1 (en) * 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2006073443A2 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
US8303955B2 (en) * 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
HUE049849T2 (hu) * 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
ES2709654T3 (es) * 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
CN107922501A (zh) 2018-04-17
ES2969968T3 (es) 2024-05-23
US20170058038A1 (en) 2017-03-02
JP2021185169A (ja) 2021-12-09
EP3344655A1 (en) 2018-07-11
EP3344655B1 (en) 2023-07-26
PH12018500445B1 (en) 2022-08-10
AU2016317028B2 (en) 2021-09-09
MX2018002447A (es) 2018-06-15
HUE063528T2 (hu) 2024-01-28
PL3344655T3 (pl) 2024-02-19
CL2018000317A1 (es) 2018-07-20
AU2016317028A1 (en) 2018-02-22
US20230265203A1 (en) 2023-08-24
DK3344655T5 (da) 2024-10-07
PH12018500445A1 (en) 2018-09-10
MX390653B (es) 2025-03-21
KR20180039172A (ko) 2018-04-17
JP2018529661A (ja) 2018-10-11
US20190177420A1 (en) 2019-06-13
BR112018001907A2 (pt) 2018-09-25
WO2017040566A1 (en) 2017-03-09
DK3344655T3 (da) 2023-10-09

Similar Documents

Publication Publication Date Title
US20230265203A1 (en) Use of anti-cd40 antibodies for treatment of lupus nephritis
KR101760242B1 (ko) 항-ｃｄ40 항체
JP6289375B2 (ja) 抗ｉｌ−３６ｒ抗体
US9260515B2 (en) Antibodies to human GDF8
US8414890B2 (en) Human antibodies to human RANKL, encoding nucleic acids and methods of treatment
US20240287198A1 (en) Anti-cd40 antibodies for use in prevention of graft rejection
KR20160129698A (ko) 항-b7-h5 항체 및 이의 용도
JP2021529754A (ja) 自己免疫疾患の処置における使用のための抗ｃｄ４０抗体
CN111511760A (zh) 对btn2具有特异性的抗体及其用途
CA3143087A1 (en) Antibodies and methods of use
JP2023537078A (ja) ＣＯＶＩＤ－１９を治療及び防止するためのＳＡＲＳ－ＣｏＶ－２抗体
KR20230022246A (ko) 치료 항체 및 그의 용도
JP2018529747A (ja) 多発性硬化症を治療するための方法
EA039944B1 (ru) Применение антител к cd40 для лечения волчаночного нефрита
KR20260013511A (ko) 암 치료를 위한 조합 요법
WO2024170543A1 (en) Anti-cd44 antibodies and uses thereof
CN121443309A (zh) 多发性骨髓瘤的治疗
KR20250077505A (ko) 항-c1q 항체를 위한 제형
EA049813B1 (ru) Антитела и способы их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210816

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241216

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250416

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260220